We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GAO: FDA Makes Headway on Compounding Regulations, but Progress is Slow
GAO: FDA Makes Headway on Compounding Regulations, but Progress is Slow
Outsourcing facilities and states have faulted the FDA for sluggish progress toward finalizing guidance documents on drug compounding and the differences between state and agency inspection protocols, according to the U.S. Government Accountability Office.